StockData
Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc. (MRVI) stock

MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)

Close on Nov 17, 2026Market cap $1.89BP/E –Yield –

Maravai LifeSciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Maravai LifeSciences's total debt was $147.11M at Jun 30, 2026. For fiscal 2025 it was $291.77M, down 1.4% from the year before. The highest annual figure on record is $534.61M in fiscal 2020.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$291.77M-1.4%
FY2024Dec 31, 2024$295.93M-43.5%
FY2023Dec 31, 2023$524.15M-0.6%
FY2022Dec 31, 2022$527.44M-0.6%
FY2021Dec 31, 2021$530.59M-0.8%
FY2020Dec 31, 2020$534.61M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$147.11M-49.9%
Q1 FY2026Mar 31, 2026$241.01M-18.3%
Q4 FY2025Dec 31, 2025$291.77M-1.4%
Q3 FY2025Sep 30, 2025$292.82M-43.9%
Q2 FY2025Jun 30, 2025$293.88M-43.8%
Q1 FY2025Mar 31, 2025$294.94M-43.6%
Q4 FY2024Dec 31, 2024$295.93M-43.5%
Q3 FY2024Sep 30, 2024$521.72M-0.6%
Q2 FY2024Jun 30, 2024$522.52M-0.6%
Q1 FY2024Mar 31, 2024$523.33M-0.6%
Q4 FY2023Dec 31, 2023$524.15M-0.6%
Q3 FY2023Sep 30, 2023$524.96M-0.6%
Q2 FY2023Jun 30, 2023$525.78M-0.6%
Q1 FY2023Mar 31, 2023$526.60M-0.6%
Q4 FY2022Dec 31, 2022$527.44M-0.6%
Q3 FY2022Sep 30, 2022$528.26M-0.6%
Q2 FY2022Jun 30, 2022$529.10M-0.7%
Q1 FY2022Mar 31, 2022$529.94M-0.7%
Q4 FY2021Dec 31, 2021$530.59M-0.8%
Q3 FY2021Sep 30, 2021$531.58M–
Q2 FY2021Jun 30, 2021$532.58M–
Q1 FY2021Mar 31, 2021$533.59M–
Q4 FY2020Dec 31, 2020$534.61M–

More Maravai LifeSciences figures

See a number that looks wrong?